Pricing Log in Create free account
Friday 6 November 2026 Export PVLA’s income statement to Excel — free account

Palvella Therapeutics, Inc.

PVLA Healthcare Biotechnology

Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.

EPS
−76.7%
Free cash flow
−136.4%

Quarter to June 2026, against a year earlier

171.28 14.43 +9.20%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
2/9
Altman Z
−11.49
Beneish M
1.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Palvella Therapeutics, Inc. (PVLA) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Palvella Therapeutics, Inc. (PVLA) trades at a EV/Sales of 48.1×. Over the past ten years it has ranged from −2.1× (June 2023) to 50.1× (November 2026); the current reading is higher than 100% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2023 0.5× (46.59%)
FY2022 0.9× (78.16%)
FY2021 4.1× 77.49%
FY2020 2.3× 31.63%
FY2019 1.7× 252.08%
FY2018 0.5× (95.37%)
FY2017 10.6× 89.18%
FY2016 5.6× (67.44%)
FY2015 17.3× —

Quarterly newest first

Period EV/Sales Change
Mar 2024 0.2× (55.93%)
Dec 2023 0.5× —
Sep 2023 −0.3× —
Jun 2023 −1.2× —
33 more quarters

Against its own ten years

Low −2.1× High 50.1×
Ten-year median 4.0×
Current reading's percentile 100

EV/Sales against peers

Company EV/Sales
PHVS Pharvaris N.V. compare n/m
VERA Vera Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
AUPH Aurinia Pharmaceuticals Inc compare 5.3×
ADMA ADMA Biologics Inc compare 5.8×
VCEL Vericel Corporation compare 7.6×
PVLA Palvella Therapeutics, Inc. 48.1×
IMNM Immunome, Inc. compare 121×
CLDX Celldex Therapeutics, Inc. compare 1,691×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PVLA